Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 257

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 257
---
 as such, repaid the outstanding balance of the loan 
 received in August 2023 at the amount of $325.                                              |

| b. | In January 2024, the Company received a                                                    
 $150 loan from several lenders, including from two directors of the Company (the “January  
 2024 Loan”). Pursuant to the agreement reached in October 2024 (the “2024 Amendment”)      
 with the January 2024 Loan lenders , the January 2024 Loan Agreements have been extended   
 until the earlier of an IPO consummation date, or until August 31, 2025 (the “Maturity     
 Date”), and shall bear interest at 8% per annum until maturity, commencing as of September 
 1, 2024. In addition, at the Maturity Date, the Company shall pay the Lenders an aggregate 
 risk premium equal to $50 . Furthermore, upon the occurrence of an IPO, the January 2024   
 Loan lenders shall be granted warrants to purchase such number of ordinary shares equal to 
 two times the Loan amount, based on a price per share equal to 75% of the lowest price per 
 share of the Company’ ordinary shares during the first five trading days as of such        
 IPO consummation.                                                                          |

| NOTE 7:- | COMMITMENTS AND CONTINGENCIES |

| 1. | Between September 2004                                                                                                                    
 and December 2015, the Company received funding from the Israeli Innovation Authority (the “IIA”) for its participation                   
 in certain research and development activities, based on budgets approved by the IIA, subject to the fulfillment of specified milestones. 
 The Company is committed to pay royalties to the IIA on proceeds from sale of products related to research and development activities     
 of which the IIA participates by way of grants. According to the funding terms, royalties between 3% and 4.5% are payable on sales        
 of developed products funded, up to 100% of the grant received by the Company, linked to U.S. dollar and bearing Secured Overnight        
 Financing Rate (the “SOFR”) interest rate. In the case of failure of a funded research and development activity, the                      
 Company is not obligated to pay any such royalties to the IIA. As of June 30, 2024, total contingent obligation to IIA is at the          
 amount of $2,650 (including interest at the amount of $306).                                                                              |

| 2. | In